Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Ventana Medical Systems, INC.

Approvalsdevice change approved (PMA)25 Aug 2026

Ventana Medical Systems, INC.

25 Aug 2026: Device change approved (PMA) · PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody. Recorded in the openFDA device PMA data.

View the source record

Decided
25 Aug 2026
Device
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Specialty
Pathology
Type
Supplement (Panel Track)
Reason
Labeling Change - Indications/instructions/shelf life/tradename
Reference
P990081 S060
Location
Tucson, AZ
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Ventana Medical Systems, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Ventana Medical Systems, INC. in our registers.

More in Pathology

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.